Emixustat clinical trials
Also written ACU-4429.
Includes 1 study of Emixustat hydrochloride.
How each study uses emixustat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses emixustat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Safety and Efficacy of Emixustat in Stargardt DiseaseCompletedPhase 3Kubota Vision Inc.NCT03772665Written as Emixustat
- Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt DiseaseCompletedPhase 2Kubota Vision Inc.NCT03033108Written as Emixustat
- Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic RetinopathyCompletedPhase 2Kubota Vision Inc.NCT02753400Written as emixustat hydrochloride
- Safety and Efficacy Assessment Treatment Trials of Emixustat HydrochlorideCompletedPhase 2/3Kubota Vision Inc.NCT01802866Written as ACU-4429
- Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular DegenerationCompletedPhase 1Kubota Vision Inc.NCT02130531Written as Emixustat HCl Tablet
- Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic AtrophyCompletedPhase 2Kubota Vision Inc.NCT01002950Written as ACU-4429
- Safety and Tolerability of ACU-4429CompletedPhase 1Kubota Vision Inc.NCT00703183Written as ACU-4429
- Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy SubjectsCompletedPhase 1Kubota Vision Inc.NCT00942240Written as ACU-4429
Codes
What other systems call emixustat · ClinicalTrials.gg INT000105
- MeSH (NLM) C000592692emixustatOne source NLM
- UNII (FDA) 02DZ1HBF0MEMIXUSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q25323930EmixustatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171669EmixustatOne source FDA
- DrugBank DB12608One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592692 | emixustat | One source NLM |
| UNII (FDA) | 02DZ1HBF0M | EMIXUSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q25323930 | Emixustat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171669 | Emixustat | One source FDA |
| DrugBank | DB12608 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.